Wayne Kuznar
Authored Items
By Wayne Kuznar
TOP - July 2020, Vol 13, No 4
Two studies presented at the 2020 American Association for Cancer Research virtual annual meeting confirm the value of different liquid biopsies in the early detection of different types of cancer. Read Bio ›
By Wayne Kuznar
TOP - July 2020, Vol 13, No 4
For most patients with early-stage testicular germ cell tumors, surgery is curative and mitigates the risk for long-term toxicities associated with chemotherapy and radiation, according to results presented by Clint Cary, MD, MPH, Associate Professor, Department of Urology, Indiana University School of Medicine, Indianapolis, at the 2020 Genitourinary Cancers Symposium. Read Bio ›
By Wayne Kuznar
TOP - July 2020, Vol 13, No 4
A bispecific chimeric antigen receptor (CAR) T-cell product directed against CD19 and CD22 antigens induced a complete response (CR) in 5 of 12 (42%) evaluable children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL). Read Bio ›
By Wayne Kuznar
TOP - July 2020, Vol 13, No 4
San Francisco, CA—Today, patients who receive stereotactic body radiation therapy (SBRT) for intermediate- or high-risk localized prostate cancer are not receiving concurrent androgen-deprivation therapy (ADT), despite national guideline recommendations that support the concurrent use of ADT with radiation therapy. Read Bio ›
By Wayne Kuznar
TOP - July 2020, Vol 13, No 4
The first “off-the-shelf” chimeric antigen receptor (CAR) T-cell platform targeting CD7 induced a complete response (CR) with no minimal residual disease (MRD) in 4 of the first 5 adults with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) who received treatment with the universal CAR T-cell therapy currently labeled GC027. Read Bio ›
By Wayne Kuznar
TOP - May 2020, Vol 13, No 3
San Francisco, CA—De-escalating chemotherapy based on a negative positron-emission tomography (PET) scan after 2 cycles of treatment is safe and feasible in most patients with low-volume metastatic seminoma, the most common type of testicular cancer, according to results presented at the 2020 Genitourinary Cancers Symposium. Read Bio ›
By Wayne Kuznar
TOP - May 2020, Vol 13, No 3
San Francisco, CA—Platinum-based therapy represents a new standard of care in patients with pancreatic cancer and germline BRCA or PALB2 mutation, based on data reported at the 2020 Gastrointestinal Cancers Symposium. Read Bio ›
By Wayne Kuznar
TOP - May 2020, Vol 13, No 3
San Francisco, CA—The combination of encorafenib (Braftovi) plus cetuximab (Erbitux), with or without binimetinib (Mektovi), improved the quality of life based on patient-reported assessments better than current standard of care in the treatment of patients with metastatic colorectal cancer (CRC) and BRAF V600E mutation, according to the BEACON CRC study, which was presented at the 2020 Gastrointestinal Cancers Symposium. Read Bio ›
By Wayne Kuznar
TOP - May 2020, Vol 13, No 3
San Francisco, CA—Second-line treatment with a 3-drug regimen that included the PD-1 inhibitor nivolumab (Opdivo), the VEGF receptor antagonist ramucirumab (Cyramza), and chemotherapy with the taxane paclitaxel, showed durable and impressive response rates, regardless of PD-L1 expression, in patients with advanced gastric cancers. Read Bio ›
By Wayne Kuznar
TOP - May 2020, Vol 13, No 3
San Francisco, CA—Delivering the keynote address at the 2020 Genitourinary Cancers Symposium, David F. Penson, MD, MPH, MMHC, Hamilton and Howd Chair in Urologic Oncology, Vanderbilt University Medical Center, Nashville, TN, highlighted the need to move toward patient-centered decisions beyond survival, focusing on patient-centered outcomes by integrating quality of life (QOL) and financial toxicity into the shared, treatment-related, decision-making process. Read Bio ›
By Wayne Kuznar
TOP - January 2020, Vol 13, No 1
Barcelona, Spain—Alterations in the fibroblast growth factor receptor (FGFR2)2 gene have been identified as driver mutations in cholangiocarcinoma (CCA). Durable objective responses were observed in >33% of patients with locally advanced or metastatic CCA and FGFR2 rearrangements or fusions who received treatment with pemigatinib, a selective oral inhibitor of FGFR1, FGFR2, and FGFR3. Data from the single-arm, open-label phase 2 clinical trial FIGHT-202, which was presented at the ESMO Congress 2019, revealed that investigational pemigatinib induced a response in 35.5% of the 107 patients with FGFR2 fusions or rearrangements (cohort A), with a median duration of response of 7.5 months. Read Bio ›
By Wayne Kuznar
TOP - January 2020, Vol 13, No 1
Barcelona, Spain—Ivosidenib (Tibsovo), an oral therapy that targets isocitrate dehydrogenase-1 (IDH1) mutation, significantly improved progression-free survival (PFS) in patients with advanced cholangiocarcinoma (CCA) and an IDH1 mutation, in a phase 3 clinical trial reported lead investigator Ghassan K. Abou-Alfa, MD, Medical Oncologist, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York City, at the ESMO Congress 2019. Read Bio ›
By Wayne Kuznar
TOP - January 2020, Vol 13, No 1
San Francisco, CA—We are in a “golden age” in chronic lymphocytic leukemia (CLL), according to Andrew D. Zelenetz, MD, PhD, Medical Oncologist, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York City. Read Bio ›
By Wayne Kuznar
Web Exclusives
Of the 24 patients receiving sotatercept monotherapy, 20 had primary myelofibrosis. Their median baseline hemoglobin level was 7.5 g/dL.
Read Bio ›By Wayne Kuznar
TOP - August 2016, Vol 9, No 3
Achieving balance in the appropriate use of opioids to treat cancer pain requires skill and compassion. Read Bio ›
By Wayne Kuznar
TOP - May 2013, Vol 6, No 2
Systematic application of oncology clinical pathways can reduce variation in cancer disease management and result in significant overall savings, said Jim Koeller, MS, at the Hematology/Oncology Pharmacy Association 9th Annual Conference Read Bio ›
By Wayne Kuznar
TOP - May 2013, Vol 6, No 2
Pharmacists can play a role in overcoming patients’ financial and personal obstacles to oral chemotherapy. Read Bio ›
By Wayne Kuznar
TOP - May 2013, Vol 6, No 2
Extremely high levels of methotrexate can lead to precipitation of the drug in the renal tubules, delayed drug clearance, and the potential for acute renal failure. Read Bio ›
By Wayne Kuznar
TOP - May 2013, Vol 6, No 2
About 3% to 5% of the general population is believed to have a mutation in the gene that encodes a major 5-fluorouracil (5-FU) metabolizing enzyme. Read Bio ›
By Wayne Kuznar
TOP - May 2013, Vol 6, No 2
The clinical response to regorafenib does not depend on tumor mutations. Among patients with metastatic colorectal cancer who participated in the phase 3 CORRECT (Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy) study, an analysis of tumor specimens for KRAS and PIK3CA mutations did not predict clinical benefit in the patients assigned to regorafenib compared with placebo, said Michael Jeffers, PhD. He presented the results of the study at the 2013 Gastrointestinal Cancers Symposium. Read Bio ›
By Wayne Kuznar
TOP - May 2013, Vol 6, No 2
Pharmacists can serve as an important information portal for access to investigational drugs through clinical trials or via expanded-access mechanisms. Read Bio ›
By Wayne Kuznar
TOP - May 2013, Vol 6, No 2
Jill Drury Awarded the TOP Pharmacist Award Read Bio ›
By Wayne Kuznar
Web Exclusives
Read Bio ›
CHICAGO—A fentanyl pectin nasal spray provides analgesia faster than immediate-release morphine in the treatment of breakthrough cancer pain, said Andrew Davies, MD, MSc at the 46th American Society of Clinical Oncology annual meeting.
Breakthrough cancer pain is a transient exacerbation of pain that occurs despite relatively stable and adequately controlled background pain and has a significant impact on quality of life.
By Wayne Kuznar
Web Exclusives
Read Bio ›
CHICAGO—A risk stratification schema can be used to identify older patients who are at risk of grade-3 to -5 toxicity from chemotherapy. The schema includes risk factors based on cancer type, patient age, upfront dose of chemotherapy, the chemotherapeutic regimen used, and history of falling, among others, said Arti Hurria, MD at the 46th American Society of Clinical Oncology annual meeting.
“We wanted to develop a predictive model for tolerance to therapy in older adults with cancer,” she said.
By Wayne Kuznar
Web Exclusives
Read Bio ›
CHICAGO—Bevacizumab in combination with chemotherapy followed by maintenance bevacizumab monotherapy improves progression-free survival (PFS) over chemotherapy alone in the treatment of advanced ovarian cancers, said Robert A. Burger, MD at the 46th American Society of Clinical Oncology annual meeting.
By Wayne Kuznar
Web Exclusives
Read Bio ›
CHICAGO—Denosumab delayed or prevented more skeletal-related adverse events than zoledronic acid in men with hormone-refractory prostate cancer and bone metastases.
The superior efficacy of denosumab on this end point along with its ease of administration—subcutaneous rather than intravenous—gives it an edge over zoledronic acid, said Karim Fizazi, MD, PhD, lead investigator of a study comparing the two treatments, at the 46th American Society of Clinical Oncology annual meeting.
By Wayne Kuznar
Web Exclusives
Read Bio ›
CHICAGO—Twice-daily dosing of naproxen can reduce the incidence and severity of bone pain in cancer patients being treated with pegfilgrastim, according to data presented at the 2010 annual meeting of the American Society of Clinical Oncology.